Earnings call transcript: McKesson tops Q1 2026 estimates and lifts outlook
McKesson (MCK) reported fiscal Q1 2027 adjusted EPS of $9.93, above the $9.64 estimate, and revenue of $105.38B versus $103.82B. It raised full-year adjusted EPS guidance to $44.20-$45.00 and increased its quarterly dividend by 15%. Shares rose to $877.23 and $898.87 after hours.
How this was made
The 30-second read
Why it matters
The combination of an EPS and revenue beat, a raised full-year EPS range, and improved operating leverage is a direct catalyst for re-rating. However, negative quarterly free cash flow and planned investment in AI and growth initiatives introduce a near-term cash-flow risk.
Market read
Traders can act on the fresh guidance range and the after-hours reaction, while monitoring whether cash generation improves as management ramps investment later in the year.
What to watch
Lower branded pricing and branded-to-generic conversions could pressure revenue durability, and some strength may be timing-related, increasing the risk of later comparisons.
Background
McKesson reported Q1 fiscal 2027 results and provided updated full-year guidance, including dividend growth and ongoing business separation plans.
Ticker impact
McKesson beat Q1 fiscal 2027 EPS and revenue and raised full-year adjusted EPS guidance to $44.20 to $45.00.
Bias higher on continued earnings revisions, with volatility risk if free cash flow fails to improve later in the year.
The article discloses a quantified EPS beat, a specific full-year guidance increase, and a dividend increase, all of which are direct drivers of valuation and sentiment. It also flags negative quarterly free cash flow and higher planned second-half investment, which can cap the rally if investors focus on cash generation.
Market effects
Reinforces strength in healthcare distribution and specialty/oncology growth, potentially supporting sentiment for peers tied to prescription volumes and specialty mix.
Primarily US-focused read-through via North American Pharmaceutical segment strength and FDA oncology approvals referenced by management.
Limited direct global catalyst beyond broader confidence in US healthcare services demand and specialty distribution economics.
Counterpoint
The quarter’s free cash flow was negative and management expects more second-half investment, so the earnings quality and cash conversion may not match the EPS beat.
Key entities
- companyMcKesson
Healthcare distributor reporting Q1 fiscal 2027 beat and raising full-year adjusted EPS guidance, alongside dividend increase and segment performance commentary.
- executiveBrian Tyler
CEO cited broad-based momentum and confidence to raise full-year guidance.
- executiveKenny Cheung
CFO highlighted operating leverage and lower share count from repurchases.
